TRVI · Trevi Therapeutics, Inc. · Webcasts, Transcripts & Audio
$13.43
-0.29 (-2.11%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.96B
Shares
142.56M
Volume · Nov 20
1.38M
Avg daily vol (3M)
1.97M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trevi Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Trevi Therapeutics, Inc. (TRVI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-11
Trevi Therapeutics, Inc. (TRVI) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-09
Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
Confident tone
IPF chronic cough trial execution
FDA alignment
RCC trial design and SSRE
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Trevi Therapeutics, Inc. (TRVI) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript
Positive tone
Clinical trial execution and enrollment
Non-IPF ILD chronic cough program
LAKE Phase 2B trial in RCC and SSRE
Diluted EPS
$-0.11
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-12
Trevi Therapeutics, Inc. (TRVI) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Confident tone
Competitive landscape and P2X3
Investor and analyst engagement
Refractory chronic cough Phase IIb
Diluted EPS
$-0.09
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-17
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Confident tone
FDA alignment and regulatory progress
Non-IPF ILD chronic cough indication
IPF-related chronic cough (Heduvio) Phase III program
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-03-11
Trevi Therapeutics, Inc. (TRVI) March 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-13
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
Confident tone
Regulatory milestones and FDA interactions
Refractory chronic cough (RCC) program
Safety profile and tolerability of Nalbuphine ER
Diluted EPS
$-0.08
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
Confident tone
IPF cough Phase III planning
CORAL Phase IIb results
Refractory chronic cough program
Diluted EPS
$-0.09
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-06-02
Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript
Confident tone
CORAL Phase 2b IPF Trial
FDA Regulatory Engagement
RIVER Phase 2a RCC Data
Diluted EPS
$-0.09
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript
Confident tone
RCC (refractory chronic cough) opportunity
Positive clinical readouts across Haduvio program
IPF chronic cough lead indication and CORAL Phase 2b
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript
Positive tone
HAP study and DEA scheduling risk
IPF chronic cough Phase 2b CORAL trial
New CDO Jim Cassella
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript
Positive tone
RIVER Phase 2a RCC Trial
CORAL Phase 2b IPF Chronic Cough Trial
Supportive Studies (HAP and Respiratory Physiology)
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript
Confident tone
RIVER Phase IIa trial in refractory chronic cough
CORAL Phase IIb trial in IPF chronic cough
Human abuse potential study (HAP)
Diluted EPS
$-0.11
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-20
Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript
Confident tone
Phase 2b CORAL trial in IPF chronic cough
Phase 2a RIVER trial in RCC
Human Abuse Potential (HAP) study
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.08
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.07
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Trevi Therapeutics, Inc. (TRVI) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.06
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Trevi Therapeutics, Inc. (TRVI) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.14
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Trevi Therapeutics, Inc. (TRVI) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.24
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-17
Trevi Therapeutics, Inc. (TRVI) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Trevi Therapeutics, Inc. (TRVI) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.34
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Trevi Therapeutics, Inc. (TRVI) Q2 2021 Earnings Call Transcript
Diluted EPS
$-0.49
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Trevi Therapeutics, Inc. (TRVI) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Trevi Therapeutics, Inc. (TRVI) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Trevi Therapeutics, Inc. (TRVI) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Trevi Therapeutics, Inc. (TRVI) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–30 of 30 webcasts
Key facts
CIK
1563880
CUSIP
89532M101
13F (30d)
230 filings
216 filers
Visit website
Investor relations